FindTrial
Sign In

AZATHIOPRINE IN TYPE 1 LEPROSY REACTIONS-THE LEPROSY MISSION TRUST INDIA

AZATHIOPRINE IN TYPE 1 LEPROSY REACTIONS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/12/007558
Enrollment
345
Registered
2016-12-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Leprosy Patients with Type 1 Reaction and neuritis

Interventions

Intervention1: Azathioprine, prednisolone: 1 2 3 4 5 6 7 8 9 10 11 12 Wk 4 Wk 8 Wk 12 Wk 16 Wk 20 Wk 24 Wk 28 Wk 32 Wk 36 Wk 40 Wk 44 Wk 48 Arm 1 Prednisolone Placebo

Sponsors

The Leprosy Mission Trust India
Lead Sponsor
The Leprosy Mission Trust India
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients with acute neuritis ( <6months) with or without type 1 reactions or recurrenct reactional skin lesions

Exclusion criteria

Exclusion criteria: Wt. <30Kgs; confirmed pregnancy; Patients with treatment for TB, HIV-AIDS Hypertension, or Type2 reactions, Hepatic dysfunction, bonemarrow dysfunction, unable to comply with follow-up requirement.

Design outcomes

Primary

MeasureTime frame
Recovery of nerve function and recurrence of neuritis during and after treatmentTimepoint: At entry, 3 months 6 months, 10. After completion of therapyeach patient will also be followed up at 60 weeks and at 72 weeks—

Secondary

MeasureTime frame
Recovery of nerve function and recurrence of neuritis during and after treatmentTimepoint: At entry, 3 months 6 months, 10. After completion of therapyeach patient will also be followed up at 60 weeks and at 72 weeks—

Countries

India

Contacts

Public ContactDr PSS Sunder Rao

The Leprosy Mission Trust India

sundarraopss@rocketmail.com9341286049

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 27, 2026